Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Macular Degeneration Treatment Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The market for macular degeneration treatments has experienced substantial expansion lately, projecting a rise from $12.38 billion in 2025 to $13.81 billion in 2026, which represents a compound annual growth rate (CAGR) of 11.5%. This recent growth trajectory is underpinned by several key factors, including a continuously aging worldwide demographic, a higher incidence of age-related macular degeneration, the demonstrated efficacy of anti-VEGF therapies in clinical settings, advancements in vision diagnostic tools, and broader availability of expert eye care services.
The market for treating macular degeneration is poised for substantial expansion in the coming years, projected to reach $20.74 billion by 2030, driven by a compound annual growth rate of 10.7%. This upward trajectory is fueled by several key factors, including the escalating global aging population, increased funding allocated to cutting-edge retinal treatments, a heightened emphasis on managing early-stage AMD, the wider implementation of gene and regenerative therapies, and greater expenditure on ocular health. Throughout this projected period, significant developments are anticipated to shape the market, such as a greater concentration on early detection and controlling disease advancement, the increasing use of anti-VEGF therapies, a growing need for treatments aimed at preserving vision long-term, the proliferation of less invasive therapeutic approaches, and heightened public consciousness regarding age-related eye conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5799&type=smp
Macular Degeneration Treatment Market Industry Drivers: What Is Driving Revenue Growth?
The escalating prevalence of retinal conditions is anticipated to be a significant catalyst for the expansion of the market focused on treating macular degeneration. These afflictions impact the crucial retinal tissue, thereby fundamentally altering how individuals perceive and process visual input, which can result in blurred or entirely lost sight. To illustrate, data from the American Academy of Ophthalmology indicates that by the year 2050, an estimated 7.32 million individuals in the U.S. will be diagnosed with primary open-angle glaucoma, an umbrella term for several eye conditions. This condition disproportionately affects those aged 70 to 79 (32% of cases), women (50%), and Hispanic individuals (50%), with Hispanic men representing the most substantial demographic segment within this group. Consequently, the growing public health challenge posed by retinal disorders is directly fueling the advancement of the macular degeneration treatment market.
Macular Degeneration Treatment Market Segment Analysis Highlighting Growth Areas
The macular degeneration treatment market covered in this report is segmented –
1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD
2) By Route of Administration: Oral, Injectable, Other Routes of Administration
3) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals
Subsegments:
1) By Early-Stage AMD: Nutritional Supplements, Lifestyle Modification Treatments
2) By Intermediate AMD: Regular Disease Monitoring and Imaging Surveillance, Risk-Factor Management and Lifestyle Modification
3) By Late-Stage AMD: Surgical Treatments, Advanced Anti-VEGF Therapies, Gene Therapy Options
#Macular Degeneration Treatment Market Growth Trends: What Is Influencing The Future Outlook?
Leading entities within the macular degeneration treatment sector are prioritizing the creation of biosimilar alternatives for age-related macular degeneration (AMD) management, aiming to broaden access to proven therapeutic solutions. Biosimilars are essentially close replicas of existing approved biological medicines, exhibiting no significant distinctions in their safety profiles, purity, or effectiveness when compared to their reference counterparts. Illustrating this trend, two biosimilars, Yesafili and Opuviz, gained FDA approval in May 2024, following submissions by Biocon Biologics Ltd., an Indian firm, and Samsung Bioepis Co. Ltd., a South Korean enterprise. These newly sanctioned treatments function by obstructing vascular endothelial growth factor (VEGF), a key contributor to aberrant blood vessel proliferation within the eye, thereby aiding in the preservation of vision threatened by conditions such as AMD and diabetic retinopathy. The Food and Drug Administration’s validation was underpinned by comparative analyses demonstrating that Yesafili and Opuviz exhibit comparable safety and efficacy to Eylea, a requirement met through extensive evaluations of their pharmacokinetic properties and immunogenic potential.
Macular Degeneration Treatment Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc
Access The Complete Macular Degeneration Treatment Market Report:
Macular Degeneration Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the macular degeneration treatment market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
